- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05286372
Ett utökat åtkomstprotokoll för mellanstorlek av AMX0035 för ALS
Ett utökat åtkomstprotokoll i mellanstorlek för att tillhandahålla AMX0035, en fast kombination av natriumfenylbutyrat (PB) och Taurursodiol (TURSO), för behandling av vuxna patienter med amyotrofisk lateralskleros (ALS)
The Expanded Access Program will provide access and assess the safety of AMX0035 for the treatment of people living with ALS.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the endoplasmic reticulum (ER) and mitochondria. This Expanded Access Program is designed to provide expanded access to AMX0035 for the treatment of people living with ALS and assess safety in diverse populations/stages of ALS over 48 weeks.
Studietyp
Utökad åtkomsttyp
- Befolkning av medelstor storlek
Kontakter och platser
Studieorter
-
-
California
-
Los Angeles, California, Förenta staterna, 90033
- University of Southern California
-
Oakland, California, Förenta staterna, 94612
- The Kaiser Permanente Medical Group
-
-
Florida
-
Fort Lauderdale, Florida, Förenta staterna, 33308
- Holy Cross Health
-
Fort Lauderdale, Florida, Förenta staterna, 32608
- Nova Southeastern University
-
Gainesville, Florida, Förenta staterna, 32608
- University of Florida
-
-
Illinois
-
Chicago, Illinois, Förenta staterna, 60614
- Northwestern University
-
-
Kansas
-
Kansas City, Kansas, Förenta staterna, 66103
- University of Kansas Medical Center
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- The Sean M. Healey & AMG Center for ALS Massachusetts General Hospital
-
-
Minnesota
-
Rochester, Minnesota, Förenta staterna, 55905
- Mayo Clinic
-
-
Nebraska
-
Lincoln, Nebraska, Förenta staterna, 68510
- Neurology Associates, P.C. / Somnos Clinical Research
-
-
New York
-
New York, New York, Förenta staterna, 10032
- Columbia University Medical Center
-
-
North Carolina
-
Durham, North Carolina, Förenta staterna, 27705
- Duke University Medical Center
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, Förenta staterna, 19107
- Thomas Jefferson University Weinberg ALS Center
-
-
Texas
-
El Paso, Texas, Förenta staterna, 79995
- Texas Tech University Health Sciences Center El Paso
-
-
Virginia
-
Richmond, Virginia, Förenta staterna, 23298
- Virginia Commonwealth University
-
-
Washington
-
Seattle, Washington, Förenta staterna, 98195
- University of Washington School of Medicine
-
Seattle, Washington, Förenta staterna, 98122
- Swedish Neuroscience Institute
-
Spokane, Washington, Förenta staterna, 99202
- Providence St. Luke's Rehabilitation Medical Center
-
-
Wisconsin
-
Madison, Wisconsin, Förenta staterna, 53705
- University of Wisconsin
-
-
-
-
-
San Juan, Puerto Rico, 00936
- Hispanic Alliance for Research & Translational Research
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
-
Male or female, at least 18 years of age (inclusive);
-
Diagnosis of ALS made by a physician experienced with the management of ALS;
-
>36 months from symptom onset defined as first weakness
-
Capable of providing informed consent;
-
Capable of and willing to follow program procedures.
-
Participants who have established care with a physician experienced in treating patients with ALS involved in the program and will maintain this clinical care throughout the duration of their time in the program.
-
Women of childbearing potential (e.g., not post-menopausal for at least one year or surgically sterile) must agree to use adequate birth control for the duration of the program and 3 months after last dose of AMX0035;
- Women must not be planning to become pregnant for the duration of the program and 3 months after last dose of study drug
-
Men must agree to practice contraception for the duration of the program and for at least 3 months after last dose of program drug;
- Men must not plan to father a child or provide sperm
Exclusion Criteria
-
Currently enrolled in a therapeutic study involving the use of an investigational therapy;
-
Dependence on invasive mechanical ventilation, defined as being unable to lay supine without it, unable to sleep without it, or continuous daytime use; presence of tracheostomy at Screening;
- No current need for tracheostomy or PAV (defined as more than 22 hours daily of mechanical ventilation for more than one week (7 days) or based on the site investigator's judgment; no need anticipated for the next 12 weeks
-
In the judgment of the Investigator, the participant's expected survival is less than 6 months
-
History of known allergy to the following: PB, bile salts, excipient/constituents of the formulation;
-
Abnormal liver function defined as AST and/or ALT >3 times the upper limit of the normal (obtained within 12 weeks from first dose);
-
Renal insufficiency as defined by eGFR <60 mL/min/1.73m2 (obtained within 12 weeks from first dose);
-
Pregnant women or women currently breastfeeding;
-
Current severe biliary disease which may result in the investigator medical judgement in biliary obstruction including for example active cholecystitis, primary biliary cirrhosis, sclerosing cholangitis, gallbladder cancer, gallbladder polyps, gangrene of the gallbladder, abscess of the gallbladder;
-
History of Class III/IV heart failure (per New York Heart Association - NYHA);
-
Participant under severe salt restriction where the added salt intake due to treatment would put the participant at risk, in the Site Investigator clinical judgment;
-
Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that would impair ability of the participant to provide informed c consent, according to Site Investigator judgment;
-
Clinically significant unstable medical condition (other than ALS) that would pose a risk to the participant if they were to participate in the program, according to Site Investigator judgment;
-
Treatment, current or within 90 days from screening with any cell therapies or gene therapies;
-
Implantation of Diaphragm Pacing System (DPS);
-
Anything that, in the opinion of the Site Investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the program;
-
Current or planned exposure to any prohibited medications listed in Section 6.8.1 of the protocol
Studieplan
Hur är studien utformad?
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
- Sjukdomar i centrala nervsystemet
- Sjukdomar i nervsystemet
- Neuromuskulära sjukdomar
- Metaboliska sjukdomar
- Neurodegenerativa sjukdomar
- Ryggmärgssjukdomar
- TDP-43 Proteinopatier
- Proteostasbrister
- Motorneuronsjuka
- Närings- och metabola sjukdomar
- Amyotrofisk lateral skleros
- natriumfenylbutyrat och taurursodiol
Andra studie-ID-nummer
- A35-006
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .